Skip to main content

This site is intended for healthcare professionals outside of the United States (US) and the United Kingdom (UK).

This site is created and funded by Novartis.

If you are an HCP from one of the countries listed, you may select your country from the list to be redirected to your specific site.

Change country or language (Non-US)
  • International
  • https://rltcare.novartis.com/
    Global
  • https://rltcare.novartis.com/de-de/
    Germany
  • https://rltcare.novartis.com/es-es/
    Spain
  • https://www.rltcare.novartis.com/fr-fr/
    France
  • https://www.rltcare.novartis.com/pt-pt/
    Portugal
  • https://www.rltcare.novartis.com/br-pt/
    Brazil
  • https://www.rltcare.novartis.com/jp-ja/
    Japan
By entering the site: I confirm that I am a healthcare professional from outside of the US and the UK.
Learn from experts to prepare your center

Radioligand Therapy: Case Study 2

This case study highlights a patient who initially responded to 177Lu-PSMA-617 but showed disease progression and rising PSA levels after two cycles, leading to the discontinuation of the therapy.

Get in touch

Our dedicated RLT specialist teams aim to streamline care coordination and alleviate uncertainty, ensuring you and your patients feel confident and supported every step of the way.

Contact us
FA-11509130 I September 2025

This international website is intended for healthcare professionals (HCPs) outside of the United States and the United Kingdom. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for prescribing information.